SCHEMBL17487385

SCHEMBL17487385

Nc1ccc2[nH]c(NCc3ccc(-c4ccccc4)cc3)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
TP53 P04637 2/20 0.58
HDAC6 Q9UBN7 2/20 0.56
LMNA P02545 3/20 0.51
HTT P42858 2/20 0.51
GFER P55789 2/20 0.51
HIF1A Q16665 1/20 0.51
HDAC1 Q13547 1/20 0.47
NPC1 O15118 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
XDH P47989 1/20 0.46
GAA P10253 2/20 0.44
PI4KA P42356 2/20 0.42
PI4K2B Q8TCG2 2/20 0.42
PI4K2A Q9BTU6 2/20 0.42
PI4KB Q9UBF8 2/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487328 0.86 RAB9A (0.54) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL17487324 0.85 RAB9A (0.51) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL17488036 0.84 RAB9A (0.50) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL15416993 0.84 RAB9A (0.82) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL17487761 0.83 RAB9A (0.44) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL3236154 0.81 RAB9A (0.77) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL17487921 0.80 RAB9A (0.52) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL17487306 0.80 HDAC6 (0.53) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL17487664 0.79 DGAT1 (0.42) RAB9ASMN1; SMN2TP53HDAC6LMNA
SCHEMBL18965942 0.79 RAB9A (0.41) RAB9ASMN1; SMN2TP53HDAC6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 RAB9A 3982/4885SMN1; SMN2 3381/4885TP53 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.